Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study - Wikidata - wikimedia - TriplyDB

Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study

Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study

http://www.wikidata.org/entity/Q35114038

about

Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers Sunitinib as salvage treatment including potent anti-tumor activity in carcinomatous ulcers for patients with multidrug-resistant metastatic breast cancer Targeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small molecule.Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review.Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm,

P2860

Q28080469-DEA43AB4-8900-40E6-A4E0-ED2666B799F2 Q28082793-E15B2BC2-6F49-4DC1-81A0-DE5EDEE171C4 Q33434465-B45E1643-FA08-4E23-BC9A-FE43455EF799 Q33913901-2EC57A26-A180-4B39-A7AC-E74E94C6AA2E Q35583942-927B1C41-BCE6-4492-8D35-BB55AE3386E5 Q35703904-5B4B738B-34A1-4FB5-947F-DC618C9776E4 Q37496378-B13705CA-B40A-4125-A973-ECCFA84B91CB

P2860

Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study

http://www.wikidata.org/entity/Q35114038

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Sunitinib in combination with ...... results from a phase II study

@ast

Sunitinib in combination with ...... results from a phase II study

@en

type

label

Sunitinib in combination with ...... results from a phase II study

@ast

Sunitinib in combination with ...... results from a phase II study

@en

prefLabel

Sunitinib in combination with ...... results from a phase II study

@ast

Sunitinib in combination with ...... results from a phase II study

@en

P1433

Q35114038-433E6471-CBF6-4F2A-BE09-171611BCDA8A

P1476

Q35114038-90AB48B6-688F-42E9-884C-2A7FC25A2165

P2093

Q35114038-0DF68194-48A7-437E-AE76-E0FDB11A4DFF

Q35114038-1101DB11-07CA-449F-ACF1-DD5E11E8E340

Q35114038-50CB66A5-2473-4858-A75E-661821F988A9

Q35114038-5554F52A-C27D-4724-99A8-849B02E186C1

Q35114038-5FB5F14E-47AD-45B0-9D5F-987FF370BCB4

Q35114038-847DFDFD-6A1B-4625-833B-4FA604A7F054

Q35114038-9AEA9A93-F99B-472E-9B23-9715ED122DA6

Q35114038-A6036F6B-D9B7-4E53-B3D7-7A9F658EE26E

Q35114038-C8DAD7C4-A7A9-4366-9B29-E38BE60E7CB7

Q35114038-CD56A8DB-0193-4C1F-A5D4-24DCB339DB45

P2860

Q35114038-0A34DF20-43CF-4135-8F7F-AF00F4E5A8C3

Q35114038-0AC1B778-59BC-471B-AC14-6A7F2CBB57A8

Q35114038-12236740-2540-4266-B249-52C7B8DF6B61

Q35114038-1528CC7A-B8E4-4C8B-85B4-9F68442537BB

Q35114038-29E8835E-CB79-4FC0-BD64-23898FF3CF7F

Q35114038-2B0F9199-D3B1-4F4E-AAF0-6F390C798D44

Q35114038-2EEDD600-6249-4B34-B008-34176A5437FF

Q35114038-2EFB6DB0-C98D-4AC6-8A6A-7B91AB1F2BD1

Q35114038-2F8CBFDE-37FA-4CFE-BB19-ECC33693B664

Q35114038-35394E73-576D-4D77-B5CE-A8ADAE4B01D7

P2888

Q35114038-5D18237C-D344-466C-8844-1540C22A389C

P304

Q35114038-857E18FB-9050-4F28-B7E4-EE84419AFC6E

P31

Q35114038-44EE1BDC-1D49-4C2F-B64E-21002A10832B

P356

Q35114038-FA880AED-0FB3-4AA3-AF09-FB358C8D500E

P407

Q35114038-F7F0D651-B485-43A6-8152-476226BB36EB

P478

Q35114038-56E6B847-AB16-4FBC-927F-989B57C87234

P50

Q35114038-2C60E783-58C7-4F2E-AB60-6BAD073C161E

Q35114038-A117E3D6-23D1-452F-A92E-6CDD1359C2D9

Q35114038-E3EAB70B-A29D-4DB6-BF53-6DD25EC616BE

Q35114038-ED30B462-A20C-4A84-9DC7-ACCE173DFE4D

P577

Q35114038-D8BED359-25D3-4A2D-A850-B6B816F8A605

P5875

Q35114038-2EFCD645-B4C8-4C3A-A2D2-3D49EA4458C9

P6179

Q35114038-9E0B07CD-78BD-44C3-891A-AA521544BBB0

P698

Q35114038-5CB76E85-C28E-4CED-8AD0-27921B850117

P932

Q35114038-96501CB9-2BEE-4798-9BB8-CE874FE7A59E

P356

1471-2407-14-166

P1433

P1476

Sunitinib in combination with ...... results from a phase II study

@en

P2093

Catherine Prady

http://www.w3.org/2001/XMLSchema#string

Kenneth A Kern

http://www.w3.org/2001/XMLSchema#string

Mark F Kozloff

http://www.w3.org/2001/XMLSchema#string

Maya Gutierrez

http://www.w3.org/2001/XMLSchema#string

Reza Khosravan

http://www.w3.org/2001/XMLSchema#string

Rossano Cesari

http://www.w3.org/2001/XMLSchema#string

Sunil Verma

http://www.w3.org/2001/XMLSchema#string

Thomas Bachelot

http://www.w3.org/2001/XMLSchema#string

Vanessa Tassell

http://www.w3.org/2001/XMLSchema#string

Xin Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Cardiac dysfunction in the trastuzumab clinical trials experience

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.

Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3

P2888

1471-2407-14-166

P304

166

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-14-166

http://www.w3.org/2001/XMLSchema#string

P407

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Jose A Garcia-Saenz

P577

2014-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260644264

http://www.w3.org/2001/XMLSchema#string

P6179

1008030389

http://www.w3.org/2001/XMLSchema#string

P698

24606768

http://www.w3.org/2001/XMLSchema#string

P932

3995914

http://www.w3.org/2001/XMLSchema#string